Systemic Pharmacokinetics and Cellular Pharmacology of Zidovudine in Human Immunodeficiency Virus Type 1–Infected Women and Newborn Infants
John H. Rodman(St. Jude Children's Research Hospital), Arnold Fridland(St. Jude Children's Research Hospital), Patricia M. Flynn(St. Jude Children's Research Hospital), Brian L. Robbins(University of North Carolina at Chapel Hill), Suzette Blanchard(Rutgers, The State University of New Jersey), José F. Rodrígúez(Consejo Superior de Investigaciones Científicas), Arlene Bardeguez(University Hospital, Newark)
Cited by 61
Related Papers
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant
|New England Journal of Medicine|1996|817
MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
|Nature Medicine|1999|580
Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1998|501
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention
|New England Journal of Medicine|2016|348